Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology.
Okrah K, Tarighat S, Liu B, Koeppen H, Wagle MC, Cheng G, Sun C, Dey A, Chang MT, Sumiyoshi T, Mounir Z, Cummings C, Hampton G, Amler L, Fridlyand J, Hegde PS, Turley SJ, Lackner MR, Huang SM. Okrah K, et al. Among authors: hegde ps. NPJ Precis Oncol. 2018 Nov 15;2:25. doi: 10.1038/s41698-018-0068-8. eCollection 2018. NPJ Precis Oncol. 2018. PMID: 30456308 Free PMC article.
Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma.
Li C, Takahashi C, Zhang L, Huseni M, Stankovich B, Mashhedi H, Lee J, French D, Anderson JE, Kim D, Howell K, Brauer MJ, Kowanetz M, Yan Y, Humke E, Ebens A, Hampton G, Lackner MR, Hegde P, Jia S. Li C, et al. J Transl Med. 2013 Mar 23;11:76. doi: 10.1186/1479-5876-11-76. J Transl Med. 2013. PMID: 23522020 Free PMC article.
Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing.
Zhang L, Chen L, Sah S, Latham GJ, Patel R, Song Q, Koeppen H, Tam R, Schleifman E, Mashhedi H, Chalasani S, Fu L, Sumiyoshi T, Raja R, Forrest W, Hampton GM, Lackner MR, Hegde P, Jia S. Zhang L, et al. Oncologist. 2014 Apr;19(4):336-43. doi: 10.1634/theoncologist.2013-0180. Epub 2014 Mar 24. Oncologist. 2014. PMID: 24664487 Free PMC article.
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
Patil NS, Righi L, Koeppen H, Zou W, Izzo S, Grosso F, Libener R, Loiacono M, Monica V, Buttigliero C, Novello S, Hegde PS, Papotti M, Kowanetz M, Scagliotti GV. Patil NS, et al. Among authors: hegde ps. J Thorac Oncol. 2018 Jan;13(1):124-133. doi: 10.1016/j.jtho.2017.09.1968. Epub 2017 Oct 24. J Thorac Oncol. 2018. PMID: 29079455 Free article.
Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab.
Vennapusa B, Baker B, Kowanetz M, Boone J, Menzl I, Bruey JM, Fine G, Mariathasan S, McCaffery I, Mocci S, Rost S, Smith D, Dennis E, Tang SY, Damadzadeh B, Walker E, Hegde PS, Williams JA, Koeppen H, Boyd Z. Vennapusa B, et al. Among authors: hegde ps. Appl Immunohistochem Mol Morphol. 2019 Feb;27(2):92-100. doi: 10.1097/PAI.0000000000000594. Appl Immunohistochem Mol Morphol. 2019. PMID: 29346180 Free PMC article.
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Şenbabaoğlu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Höglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T. Mariathasan S, et al. Among authors: hegde ps. Nature. 2018 Feb 22;554(7693):544-548. doi: 10.1038/nature25501. Epub 2018 Feb 14. Nature. 2018. PMID: 29443960 Free PMC article.
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G, Malboeuf C, Lieber DS, Lipson D, Silterra J, Amler L, Riehl T, Cummings CA, Hegde PS, Sandler A, Ballinger M, Fabrizio D, Mok T, Shames DS. Gandara DR, et al. Among authors: hegde ps. Nat Med. 2018 Sep;24(9):1441-1448. doi: 10.1038/s41591-018-0134-3. Epub 2018 Aug 6. Nat Med. 2018. PMID: 30082870
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Kowanetz M, Zou W, Gettinger SN, Koeppen H, Kockx M, Schmid P, Kadel EE 3rd, Wistuba I, Chaft J, Rizvi NA, Spigel DR, Spira A, Hirsch FR, Cohen V, Smith D, Boyd Z, Miley N, Flynn S, Leveque V, Shames DS, Ballinger M, Mocci S, Shankar G, Funke R, Hampton G, Sandler A, Amler L, Mellman I, Chen DS, Hegde PS. Kowanetz M, et al. Among authors: hegde ps. Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10119-E10126. doi: 10.1073/pnas.1802166115. Epub 2018 Oct 8. Proc Natl Acad Sci U S A. 2018. PMID: 30297397 Free PMC article. Clinical Trial.
97 results